View Item 

Show simple item record

Patiromer for the management of hyperkalaemia in patients receiving renin- angiotensin- aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial

dc.contributor.authorButler, Javed
dc.contributor.authorAnker, Stefan D.
dc.contributor.authorSiddiqi, Tariq Jamal
dc.contributor.authorCoats, Andrew J.S.
dc.contributor.authorDorigotti, Fabio
dc.contributor.authorFilippatos, Gerasimos
dc.contributor.authorFriede, Tim
dc.contributor.authorGöhring, Udo-Michael
dc.contributor.authorKosiborod, Mikhail N.
dc.contributor.authorLund, Lars H.
dc.contributor.authorMetra, Marco
dc.contributor.authorMoreno Quinn, Carol
dc.contributor.authorPiña, Ileana L.
dc.contributor.authorPinto, Fausto J.
dc.contributor.authorRossignol, Patrick
dc.contributor.authorSzecsödy, Peter
dc.contributor.authorVan Der Meer, Peter
dc.contributor.authorWeir, Matthew
dc.contributor.authorPitt, Bertram
dc.date.accessioned2022-02-07T20:23:33Z
dc.date.available2023-02-07 15:23:32en
dc.date.available2022-02-07T20:23:33Z
dc.date.issued2022-01
dc.identifier.citationButler, Javed; Anker, Stefan D.; Siddiqi, Tariq Jamal; Coats, Andrew J.S.; Dorigotti, Fabio; Filippatos, Gerasimos; Friede, Tim; Göhring, Udo-Michael ; Kosiborod, Mikhail N.; Lund, Lars H.; Metra, Marco; Moreno Quinn, Carol; Piña, Ileana L. ; Pinto, Fausto J.; Rossignol, Patrick; Szecsödy, Peter ; Van Der Meer, Peter; Weir, Matthew; Pitt, Bertram (2022). "Patiromer for the management of hyperkalaemia in patients receiving renin- angiotensin- aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial." European Journal of Heart Failure 24(1): 230-238.
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.urihttps://hdl.handle.net/2027.42/171557
dc.publisherJohn Wiley & Sons, Ltd.
dc.subject.otherHyperkalaemia
dc.subject.otherHeart failure
dc.subject.otherTrial design
dc.subject.otherAdherence
dc.subject.otherMineralocorticoid receptor antagonists
dc.subject.otherRenin- angiotensin- aldosterone system inhibitors
dc.subject.otherPatiromer
dc.subject.otherPotassium
dc.titlePatiromer for the management of hyperkalaemia in patients receiving renin- angiotensin- aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171557/1/ejhf2386_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171557/2/ejhf2386.pdf
dc.identifier.doi10.1002/ejhf.2386
dc.identifier.sourceEuropean Journal of Heart Failure
dc.identifier.citedreferenceSeliger SL. Hyperkalemia in patients with chronic renal failure. Nephrol Dial Transplant. 2019; 34 ( Suppl 3 ): iii12 - 8.
dc.identifier.citedreferencePonikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18: 891 - 975.
dc.identifier.citedreferenceClinicalTrials.gov. Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone (REALIZE- K). [cited 2021 Sep 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT04676646.
dc.identifier.citedreferenceClinicalTrials.gov. Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure (PRIORITIZE HF). [cited 2021 Aug 19]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03532009.
dc.identifier.citedreferenceUS Food and Drug Administration. Lokelma prescribing information. 2018 [cited 2021 Aug 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207078s000lbl.pdf.
dc.identifier.citedreferenceRossignol P, Lainscak M, Crespo- Leiro MG, Laroche C, Piepoli MF, Filippatos G, et al.; Heart Failure Long- Term Registry Investigators Group. Unravelling the interplay between hyperkalaemia, renin- angiotensin- aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC- HFA- EORP Heart Failure Long- Term Registry. Eur J Heart Fail. 2020; 22: 1378 - 89.
dc.identifier.citedreferenceSavarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlström U, et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11- 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2018; 20: 1326 - 34.
dc.identifier.citedreferenceMaggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, et al.; Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long- Term Registry. Eur J Heart Fail. 2013; 15: 1173 - 84.
dc.identifier.citedreferenceBeusekamp JC, Tromp J, van der Wal HH, Anker SD, Cleland JG, Dickstein K, et al. Potassium and the use of renin- angiotensin- aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT- CHF. Eur J Heart Fail. 2018; 20: 923 - 30.
dc.identifier.citedreferenceCooper LB, Benson L, Mentz RJ, Savarese G, DeVore AD, Carrero JJ, et al. Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. Eur J Heart Fail. 2020; 22: 1390 - 8.
dc.identifier.citedreferenceBandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, et al. Hyperkalemia after initiating renin- angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc. 2017; 6: e005428.
dc.identifier.citedreferenceYancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; 134: e282 - 93.
dc.identifier.citedreferenceMcDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42: 3599 - 726.
dc.identifier.citedreferenceUS Food and Drug Administration. FDA Drug Safety Communication: FDA recommends separating dosing of potassium- lowering drug sodium polystyrene sulfonate (Kayexalate) from all other oral drugs. 2017 September 6 [cited 2021 Aug 19]. Available from: https://www.fda.gov/drugs/drug- safety- and- availability/fda- drug- safety- communication- fda- recommends- separating- dosing- potassium- lowering- drug- sodium.
dc.identifier.citedreferencePitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015; 17: 1057 - 65.
dc.identifier.citedreferencePitt B, Bushinsky DA, Kitzman DW, Ruschitzka F, Metra M, Filippatos G, et al.; Patiromer- 204 Investigators. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Fail. 2018; 5: 257 - 66.
dc.identifier.citedreferencePitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ; PEARL- HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double- blind, placebo- controlled study in patients with chronic heart failure (the PEARL- HF) trial. Eur Heart J. 2011; 32: 820 - 8.
dc.identifier.citedreferencePocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2012; 33: 176 - 82.
dc.identifier.citedreferenceCooper LB, Savarese G, Carrero JJ, Szabo B, Jernberg T, Jonsson à , et al. Clinical and research implications of serum versus plasma potassium measurements. Eur J Heart Fail. 2019; 21: 536 - 7.
dc.identifier.citedreferenceDeFilippis EM, Reza N, Donald E, Givertz MM, Lindenfeld J, Jessup M. Considerations for heart failure care during the COVID- 19 pandemic. JACC Heart Fail. 2020; 8: 681 - 91.
dc.identifier.citedreferenceTrevisan M, Fu EL, Xu Y, Savarese G, Dekker FW, Lund LH, et al. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. Eur J Heart Fail. 2021; 23: 1698 - 707.
dc.identifier.citedreferenceBeusekamp JC, Tromp J, Cleland JGF, Givertz MM, Metra M, O’Connor CM, et al. Hyperkalemia and treatment with RAAS inhibitors during acute heart failure hospitalizations and their association with mortality. JACC Heart Fail. 2019; 7: 970 - 9.
dc.identifier.citedreferenceFerreira JP, Butler J, Rossignol P, Pitt B, Anker SD, Kosiborod M, et al. Abnormalities of potassium in heart failure: JACC state- of- the- art review. J Am Coll Cardiol. 2020; 75: 2836 - 50.
dc.identifier.citedreferenceTrevisan M, de Deco P, Xu H, Evans M, Lindholm B, Bellocco R, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018; 20: 1217 - 26.
dc.identifier.citedreferenceOuwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. Determinants and clinical outcome of uptitration of ACE- inhibitors and beta- blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017; 38: 1883 - 90.
dc.identifier.citedreferenceEpstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin- angiotensin- aldosterone system inhibitors. Am J Manag Care. 2015; 21 ( 11 Suppl ): S212 - 20.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf2386_am.pdf
Size:
491.1KB
Format:
PDF
View/Open
Name:
ejhf2386.pdf
Size:
1.318MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.